Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...

Key Takeaways Novo Nordisk's U.S.-listed shares fell Monday after it released the latest results for its developmental weight ...

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...

Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...

New trial data showed CagriSema led to 'superior' weight loss, but at a rate much less than original expectations of 25% Shares of Novo Nordisk A/S were getting hit hard in early Monday trading ...

New trial data showed CagriSema led to 'superior' weight loss, but at a rate less than expectations Shares of Novo Nordisk A/S were getting hit hard Monday, after the maker of Ozempic and Wegovy ...

Novo Nordisk shares fell after the pharmaceutical giant released fresh trial results for its CagriSema developmental weight-loss drug. The Danish company said CagriSema helped obese or overweight ...

In the REDEFINE 2 trial, CagriSema led to 15.7% weight loss after 68 weeks, compared to 3.1% with placebo, with 89.7% achieving at least 5% Novo Nordisk plans to seek regulatory approval for ...

CagriSema-treated patients achieved superior weight loss compared with those who received placebo. Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide 2.4mg and ...